Psoriatic Arthritis

WASHINGTON — Patients with inflammatory arthritis who receive rituximab, interleukin-6 inhibition or Janus kinase inhibitors demonstrate higher severe infection risks vs. TNF inhibitors, according to data presented at ACR Convergence 2024.

WASHINGTON — Dactylitis, psoriasis and other non-musculoskeletal manifestations of psoriatic arthritis can be accurately monitored through patient self-reporting, according to data presented at ACR Convergence 2024.

Hand and whole body MRI can objectively measure improvements in joint and enthesis inflammation resulting from apremilast treatment for psoriatic arthritis, according to data published in The Lancet Rheumatology.

Deucravacitinib is superior to placebo for improving response across all domains of minimal disease activity criteria in patients with psoriatic arthritis at 16 weeks, according to data published in Rheumatology.

Around the world, approximately 125 million people suffer from psoriasis and psoriatic arthritis. On Oct. 29, World Psoriasis Day, we recognize the challenges of and treatment advances for patients with psoriasis.

The FDA approved the Stelara biosimilar, Selarsdi, as a 130 mg/26 mL single-dose IV infusion for adult patients with Crohn’s disease and ulcerative colitis, Alvotech and Teva Pharmaceuticals announced in a press release.

Patients with rheumatoid arthritis or psoriatic arthritis starting biologic disease-modifying antirheumatic drugs have a higher risk for interstitial lung disease vs. the general population, with the highest risk found in RA, data show.

Ethan Craig, MD, spoke with Healio about the importance of increasing awareness of psoriatic arthritis.

Ethan Craig, MD, spoke with Healio about treatment options coming up in the pipeline for psoriatic arthritis.

Ethan Craig, MD, spoke with Healio about treatment options currently available in psoriatic arthritis.